WithdrawnNot applicableNCT01645826
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
Studying Heritable pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of South Florida
- Principal Investigator
- Mark Rumbak, MDUniversity of South Florida
- Intervention
- Diltiazem Hydrochloride(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2014
Study locations (1)
- University of South Florida, Tampa, Florida, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01645826 on ClinicalTrials.govOther trials for Heritable pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06850792imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNceUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGNCT06587074Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific TherapyRussian Cardiology Research and Production Center
- RECRUITINGNCT05462574Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)Vanderbilt University Medical Center
See all trials for Heritable pulmonary arterial hypertension →